LYNTONIX was awarded the "2025 National Innovation Excellence Award" by the Biotechnology and Medical Technology Policy Research Center Foundation, recognizing LYNTONIX's achievements and results in core technologies, commercial applications, and intellectual property patent layout.According to research findings, oral administration of LTX-568 for 30 min significantly relieved visceral pain in irritable bowel syndrome (IBS) animal models compared to existing IBS drugs. Moreover, after 10 consecutive days of treatment, the abnormal proliferation of nerve fibers in intestinal mucosal layer and the overexpression of serotonin 7 receptor were back to normal levels. These findings have been published in academic journals.
In 2024 and 2025, LTX-568 was granted the patents in Europe and China, respectively. Together with the existing patents in United States, Japan, South Korea, and Taiwan, the patent portfolio covers the major IBS pharmaceutical markets worldwide. In 2025, LYNTONIX was established, and the licensing of LTX-568 was successfully completed.
Click here to open news linkhttps://www.lyntonix.com/en/hot_526939.html[2025/12] Award-LYNTONIX won the 2025 Innovative Improvement Award2026-01-092027-01-09
According to Article 3, Paragraph 1 of “Regulations Governing the Identification of High-Risk Innovative Startups as Referred to in Article 12 of the Income Basic Tax Act”, LYNTONIX has been approved as a “High-Risk Innovative Startup”. Investments in LYNTONIX are therefore eligible for the Income Basic Tax credit.https://www.lyntonix.com/en/hot_522358.html[2025/03] News- LYNTONIX has been approved as a High-Risk Innovative Starup by Industrial Development Administration (IDA), Ministry of Economic Affairs (MOEA), Taiwan2026-01-092027-01-09
LYNTONIX attended 2025 BIO Asia and showcased the latest research data on LTX-568. During the convention, LTX-568 received strong interest and highly positive feedback from industry experts and partners. The next step for LTX-568 is to complete the GLP preclinical studies, and advance to clinical trials. Our mission is clear:Let the IBS patients regain control of their lives. LYNTONIX will keep focusing on the effective and safe thetreatment of IBS abdominal pain.https://www.lyntonix.com/en/hot_522357.html[2025/07] Exhibition announcement- LYNTONIX promoted LTX-568 in 2025 BIO Aisa2026-01-092027-01-09
LYNTONIX was honored to be one of the Taiwanese biomedical startup companies selected by NSTC to participate in 2025 US BIO, promoting our innovatice product, LTX-568. During the convention, LTX-568 attracted strong interest and received highly positive feedback from industry experts and global partners. We look forward to advancing LTX-568 into clinical studies, and conquering the unmet needs for IBS abdominal pain.https://www.lyntonix.com/en/hot_522356.html[2025/06] Exhibition announcement- LTX-568 draws global attention at the 2025 BIO International Convention2026-01-092027-01-09
BIO2025 Exhibitor Directory
https://bio2025.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=00953459https://www.lyntonix.com/en/hot_516190.html[2025/06] Exhibition announcement- LYNTONIX will participate in the US BIO 20252026-01-092027-01-09
LYNTONIX successfully completed company registration on March 25, 2025.https://www.lyntonix.com/en/hot_516388.html[2025/03] News- LYNTONIX has Completed the Company Registration2026-01-092027-01-09
https://exp.stpi.narl.org.tw/project/FITI/news/detail?id=c49966e4-145b-45a6-81b2-1378e169fcc2
國科會「創新創業激勵計畫」 113年第二梯次決選暨頒獎典禮 (2024.11.29) https://www.stpi.niar.org.tw/news/detail/8f64fa2d-2f9f-4edd-a91e-65571d16802b
經濟日報-竹科輔導4組FITI計畫團隊績效完勝 年終再獲傑出獎及潛力獎(2024.11.29) https://money.udn.com/money/story/5635/8394008
臺大藥刊 第086期 專題報導-徹底翻轉我們的創新創業激勵計劃 (2025.03.25) https://online.fliphtml5.com/ktnkc/bsrp/#google_vignette
臺大校訊 1461期-臺大腸躁症新藥團隊獲得FITI競賽創業傑出獎 (2025.04.10) https://sec.ntu.edu.tw/epaper/article.asp?num=1641&sn=35401https://www.lyntonix.com/en/hot_516193.html[2024/11] News- LYNTONIX has won the biggest award at the 2024 FITI2026-01-092027-01-09
10th Annual SPARK Global Meeting (2024.9/20) https://sparkglobal.io/10th-annual-spark-global-meeting/
科政團隊赴美參加2024 SPARK VC Day 協助新創技術募資及產業交流 (2024.11.30) https://www.stpi.niar.org.tw/news/detail/9a243d26-8dd2-4f69-9c25-cc32fdbacb77https://www.lyntonix.com/en/hot_516189.html[2024/09] News- LYNTONIX was invited to participate in the 2024 SPARK VC DAY at Stanford University2026-01-092027-01-09
https://innoaward.taiwan-healthcare.org/award_detail.php?REFDOCTYPID=0r4ggllnka0x43sh&num=1&REFDOCID=0q2p6w3o3k3zpccohttps://www.lyntonix.com/en/hot_516192.html[2023/11] Award- LYNTONIX won the 2023 Innovative Improvement Award2026-01-092027-01-09
未來科技獎(2023.10)https://www.futuretech.org.tw/futuretech/index.php?action=brands_detail&br_uid=350https://drive.google.com/file/d/1XJkfVJudtYzhqsACfMzuaooIGE3dc4FW/viewhttps://www.lyntonix.com/en/hot_516191.html[2023/10] Award- LINTONIX won the 2023 Future Tech Award2026-01-092027-01-09
https://innoaward.taiwan-healthcare.org/award_detail.php?REFDOCID=0q2p6w3o3k3zpccohttps://www.lyntonix.com/en/hot_516386.html[2019/12] Award- LYNTONIX won 16th National Innovation Award2026-01-092027-01-09